MicroRNAs play an essential role in cell homeostasis
and have been
proposed as therapeutic agents. One strategy to deliver microRNAs
is to genetically engineer target cells to express microRNAs of interest.
However, to control dosage and timing, as well as to limit potential
side-effects, microRNAs’ expression should ideally be under
exogenous, inducible control. Conditional expression of miRNA-based
short hairpin RNAs (shRNAmirs) via gene regulatory circuits such as
the Tet-system is therefore a promising strategy to control shRNAmirs’
expression in research and therapy. Single vector approaches like
Tet-On all-in-one designs are more compatible with potential clinical
applications by providing the Tet-On system components in a single
round of genetic engineering. However, all-in-one systems often come
at the expense of heterogeneous and unstable expression. In this study,
we aimed to understand the causes that lead to such erratic transgene
expression. By using a reporter cell, we found that the degree of
heterogeneity mostly correlated with reverse tetracycline transactivator
(rtTA) expression levels. Moreover, the targeted integration of a
potent rtTA expression cassette into a genomic safe harbor locus functionally
rescued previously silenced rtTA-responsive transcription units. Overall,
our results suggest that ensuring homogenous and stable rtTA expression
is essential for the robust and reliable performance of future Tet-On
all-in-one designs.